Companion Medical won FDA 510(k) approval for its wireless-enabled InPen insulin pen and mobile application. InPen is a new injector pen that actually contains computer chip technology built right into the base, including Bluetooth LE wireless capability.
By, Lisa Foster-McNulty, MSN, RN, CDE They say that a dog is man's best friend, and certainly a PWD (person with diabetes) who shares their life with a DAD (diabetes alert dog) would agree. Many people love dogs and heartwarming dog stories. Recently some researchers investigated whether dogs or CGMs (continuous glucose monitors) do a better job of detecting hypoglycemia, and the results may surprise you! While there has been much reporting of the ability of a well-trained DAD to identify hypoglycemia, there hasn’t actually been much research to determine if dogs can do a better job than other tools such as a CGM. A pediatric endocrinology fellow at Portland's Oregon Health & Science University, Dr. Evan Los, compared diabetes alert dogs against CGMs to determine which was more effective at detecting hypoglycemia. He determined that CGMs were more accurate at detecting hypoglycemia than the dogs, according to a Medscape Multispecialty report. In the study, eight people with Type 1 Diabetes who owned a diabetes alert dog were asked to use three methods of detecting lows. These methods were 1) their own self-detected symptoms, 2) their DAD, and 3) a CGM. They were asked to record which of the three methods was first to discover the hypoglycemia. The analysis showed that about 70% of the time, the CGM was first to pick up the low BG. Dogs were first 19% of the time. One disadvantage of a DAD was that they barked for lows more often than warranted, which led to some false alarms. We shouldn't be too quick to dismiss the dogs, though. This was a very small study, so it was too small of a sample size to draw any real conclusions. Dr. [...]
We inject insulin into subcutaneous fatty tissue, and when we repeatedly inject the same spots without giving them ample time to heal, we have trouble.
Among the more exciting developments from from AADE was the unveiling of Medtronic’s new 630G insulin pump, which received FDA clearance just a few days ago. I had a chance to “play around” with the new pump, and here’s what I learned...
Although the G5 Continuous Glucose Monitor (CGM)is still new, Dexcom is already working on their next development, the G6. What can we look forward to?